SynthesisEmerging infectious diseases2017
Risk Factors for Disseminated Coccidioidomycosis, United States.
Synthesis in Emerging infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed.
- Coccidioidomycosis in Patients Treated with Dupilumab: A Descriptive Case Series.Mycopathologia · 2026Article
- Immunomodulation in the Treatment of Disseminated Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Myeloid-derived suppressor cell (MDSC)-like neutrophils induced by pulmonary infection withmBio · 2026Article
- Transcriptomic characterization of Coccidioides morphological states using RiboMarker-enhanced RNA sequencing.G3 (Bethesda, Md.) · 2026Article
- Genetic and transcriptomic determinants of disseminated coccidioidomycosis identify a founder variant inmedRxiv : the preprint server for health sciences · 2026Article
- Macrophage phagocytosis ofmBio · 2026Article
- Long-term Sequelae Associated With Severe West Nile Virus Disease in Maricopa County, Arizona, 2021.Open forum infectious diseases · 2026Article
- Th2 skewing in patients with disseminated coccidioidomycosis.JCI insight · 2026Article
- Exhausted T cell phenotypes in disseminated coccidioidomycosis.JCI insight · 2026Article
- Frequency and Duration of Diagnostic Delays Associated with Coccidioidomycosis and Risk Factors for Missed Diagnoses, United States.Emerging infectious diseases · 2026Article
- The Fungus Among Us: Latency, Reactivation, and the Expanding Clinical Spectrum of Coccidioidomycosis.Cureus · 2026Review
- Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Immune-Based Prevention and Therapy Against Coccidioidomycosis: Current and Emerging Approaches.Journal of fungi (Basel, Switzerland) · 2026Review
- Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi.Antimicrobial agents and chemotherapy · 2026Review
- Isolated knee septic arthritis revealing disseminated coccidioidomycosis without apparent pulmonary involvementMedical mycology case reports · 2026Article
- Immunocompetent host and mortality-related coccidioidomycosis: A case report and narrative review.Medical mycology case reports · 2026Article
- Interferon-γ Therapy in Patients With Refractory Disseminated Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Exhausted T cell phenotypes in disseminated coccidioidomycosis.medRxiv : the preprint server for health sciences · 2026Article
- How I Treat: Infections and inborn errors of immunity-Prevention, diagnosis, and treatment.Journal of human immunity · 2026Review
- Dual Burden: Osteomyelitis Secondary to Disseminated Coccidioidomycosis in an Immunocompetent Patient.Cureus · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of 150,000 new coccidioidomycosis infections that occur annually in the United States, ≈1% disseminate; one third of those cases are fatal. Immunocompromised hosts have higher rates of dissemination. We identified 8 patients with disseminated coccidioidomycosis who had defects in the interleukin-12/interferon-γ and STAT3 axes, indicating that these are critical host defense pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.